|Bid||53.13 x 800|
|Ask||53.14 x 900|
|Day's range||52.56 - 53.61|
|52-week range||33.36 - 61.71|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||15.18|
|Earnings date||08 Feb 2022|
|Forward dividend & yield||1.60 (3.05%)|
|Ex-dividend date||27 Jan 2022|
|1y target est||N/A|
Gregory Zuckerman, author of ‘A Shot to Save the World’, joins Yahoo Finance's Editor-in-Chief, Andy Serwer, for a discussion about what COVID-19 will look like in the future.
Bank of America upgraded its rating on pharma and biotech company Moderna from “underperform” to “neutral” along with a new price target of $180 (up from $135) according to a recent BofA Global Research report. BofA cited a “more reasonable valuation” that has come about as being the main reason for the upgrade.
Dr. Michael Saag, associate dean for global health at University of Alabama-Birmingham, joins Yahoo Finance Live to discuss the importance of vaccine shots and how misinformation is impacting people's perception of the severity of COVID-19.